Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 9/20 | 0.41 |
| ▸ | IDH1 | O75874 | 9/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | INSR | P06213 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 2/20 | 0.39 |
| ▸ | LTK | P29376 | 2/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.39 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.39 |
| ▸ | MERTK | Q12866 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21354673 | 0.89 | ALK (0.41) | ALKIDH1EGFRINSRLCK | |
| SCHEMBL17583060 | 0.86 | ALK (0.43) | ALKEGFRINSRLCKLTK | |
| SCHEMBL21354728 | 0.85 | ALK (0.46) | ALKINSRLCKLTKAXL | |
| SCHEMBL23329837 | 0.85 | EGFR (0.38) | ALKIDH1EGFRINSRLCK | |
| SCHEMBL21354669 | 0.85 | ACACB (0.35) | IDH1 | |
| SCHEMBL17583031 | 0.84 | EGFR (0.52) | ALKEGFRIRAK1 | |
| SCHEMBL17586604 | 0.84 | EGFR (0.51) | ALKEGFR | |
| SCHEMBL18791485 | 0.84 | IDH1 (0.47) | IDH1 | |
| SCHEMBL17582956 | 0.83 | ALK (0.41) | ALKIDH1EGFRINSRLCK | |
| SCHEMBL17582926 | 0.83 | ALK (0.44) | ALKEGFRINSRLCKLTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062389-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | BOZIK MICHAEL E (US) | 2026-03-05 | — | — | US | disclosed |
| US-12286408-B2 | KV7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-04-29 | — | — | US | disclosed |
| US-20240002349-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2024-01-04 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2023-01-05 | — | — | US | disclosed |
| US-11261162-B2 | KV7 channel activators compositions and methods of use | KNOPP BIOSCIENCES, LLC (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KNOPP BIOSCIENCES LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KNOPP BIOSCIENCES LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2019-09-19 | — | — | US | disclosed |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | CHANNEL BIOSCIENCES, LLC | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261162-B2 | KV7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885IDH1 2551/4885EGFR 4338/4885 |
| US-20190284142-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885IDH1 2551/4885EGFR 4338/4885 |
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885IDH1 2551/4885EGFR 4338/4885 |
| US-20230000831-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885IDH1 2551/4885EGFR 4338/4885 |
| US-10851067-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885IDH1 2551/4885EGFR 4338/4885 |
| US-20260062389-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNH3, KCNA3 | ALK 478/4885IDH1 2268/4885EGFR 2207/4885 |
| US-20210130299-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885IDH1 2551/4885EGFR 4338/4885 |
| US-12286408-B2 | KV7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885IDH1 2551/4885EGFR 4338/4885 |
| US-20240002349-A1 | KV7 CHANNEL ACTIVATORS COMPOSITIONS AND METHODS OF USE | KCNA7, KCNK17, KCNAB1 | ALK 2337/4885IDH1 2551/4885EGFR 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.